Current treatment for ovarian cancer.
Current treatment for ovarian cancer.
复制标题
DOI：
10.1517/14656566.2.1.109
复制
发表时间：
2001-01-01
影响因子：
3.2
通讯作者：
Awtrey, C S
中科院分区：
文献类型：
--
作者：
Eltabbakh, G H;Awtrey, C S
卵巢癌是最致命的妇科恶性肿瘤。上皮性卵巢癌（EOC）约占卵巢癌病例的90%，70%的EOC患者出现在晚期。EOC的治疗通常包括细胞减少术，包括全腹子宫切除术（TAH）、双侧输卵管卵巢切除术（BSO）、网膜切除术和淋巴结切除术，然后进行辅助化疗。目前的辅助化疗包括紫杉醇和顺铂或卡铂，每3周给予6个周期。紫杉醇联合铂化疗在大约80%的患者中达到临床反应。然而，大多数患者在治疗后3年内会出现肿瘤复发。铂敏感肿瘤患者可再用铂和/或紫杉醇治疗。铂耐药肿瘤患者预后差，只能姑息治疗。这些患者的治疗选择包括拓扑替康、doxil、吉西他滨、依托泊苷或参加临床试验。未来的研究需要关注细胞减少手术、二次手术、巩固化疗的作用，开发新的化疗药物，化疗耐药调节剂，以及治疗女性卵巢癌的新途径。
Ovarian cancer is the most lethal gynaecologic malignancy. Epithelial ovarian cancer (EOC) constitutes approximately 90% of cases of ovarian cancer and 70% of the patients with EOC present in advanced stage. Treatment of EOC usually consists of cytoreductive surgery which includes total abdominal hysterectomy (TAH), bilateral salpingo-oophorectomy (BSO), omentectomy and lymphadenectomy followed by adjuvant chemotherapy. Current adjuvant chemotherapy includes paclitaxel and either cisplatin or carboplatin given every 3 weeks for six cycles. The combination paclitaxel and platinum chemotherapy achieves clinical response in approximately 80% of patients. However, most patients will have tumour recurrence within 3 years following treatment. Patients with platinum-sensitive tumours can be re-treated with platinum and/or paclitaxel. Those with platinum-resistant tumours have poor prognosis and treatment is palliative. Options of treatment in these patients include topotecan, doxil, gemcitabine, etoposide, or enrolment in clinical trials. Future research needs to focus on the role of cytoreductive surgery, second-look surgery, consolidation chemotherapy, development of new chemotherapeutic agents, chemoresistance modulators, as well as new approaches to the treatment of women with ovarian cancer.